<DOC>
	<DOCNO>NCT00199056</DOCNO>
	<brief_summary>The study evaluate efficacy tolerability intensify induction consolidation therapy . Thereafter patient receive individualised treatment stratify accord relapse risk stem cell transplantation patient high high risk relapse . Patients standard risk receive consolidation reinduction chemotherapy . In parallel minimal residual disease ( MRD ) evaluate . A MRD base risk stratification treatment decision develop .</brief_summary>
	<brief_title>German Multicenter Trial Treatment Newly Diagnosed Acute Lymphoblastic Leukemia Adults ( 06/99 )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>Acute lymphoblastic leukemia ( proB , common , preB , early T , T ) Age 1565 yr ( *5565 year biologically young accord general condition ) Severe comorbidity Cytostatic pretreatment Pregnancy Missing write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>ALL</keyword>
	<keyword>Treatment</keyword>
	<keyword>De Novo</keyword>
	<keyword>Adult</keyword>
</DOC>